EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Evaxion A/S

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026

$3.33+0.50 (+17.67%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Evaxion A/S income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	7.53	3.34	0.07	0	–	–	–	–
Research & Development	9.98	10	12	17	20	11	8.22	3.73
Operating Expenses	–	–	–	25	26	17	11	5.63
Operating Income	-9.23	-15	-22	-25	-26	-17	-11	-5.63
Interest Expense	4.00	3.12	1.68	1.51	0.92	0.22	1.22	0.72
Interest & Investment Income	4.62	6.50	0.96	2.83	2.04	0.22	0.07	0.08
Pretax Income	-8.62	-11	-23	-24	-25	-17	-12	-6.27
Income Tax Expense	-0.91	-0.79	-0.79	-0.77	-0.18	-1.56	-0.83	-0.74
Net Income incl. Noncontrolling Interests	-7.71	-11	-22	-23	-25	-15	-11	-5.54
Net Income	-7.71	-11	-22	-23	-25	-15	-11	-5.54
Net Income to Common	–	–	-22	-23	-25	-15	-11	-5.54
EPS (Basic)(per share)	-0.02	-0.20	-0.81	-0.98	-1.26	-0.97	-0.81	-0.43
EPS (Diluted)(per share)	–	–	-0.81	-0.98	-1.26	-0.97	-0.81	-0.43
Shares Outstanding (Basic, Weighted)(shares)	320	54	27	24	19	15	14	13
Shares Outstanding (Diluted, Weighted)(shares)	320	54	27	24	19	15	14	13

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -122.7%
Net margin: -102.4%
Return on equity, FY2025: –

Financial strength

Current ratio: 5.06
Debt to equity: –
Debt to assets: 27.4%
Cash to current liabilities: 446.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –